Clarithromycin, a cytochrome P 450 inhibitor, can reverse mefloquine resistance in Plasmodium yoelii nigeriensis-infected Swiss mice

Parasitology

Volumn 138, Issue 9, 2011, Pages 1069-1076

  Tripathi, Renu ^a   Pandey, Swaroop Kumar ^a   Rizvi, Amber ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

clarithromycin; drug resistance; malaria; mefloquine; Plasmodium yoelii nigeriensis

Indexed keywords

CLARITHROMYCIN; CYTOCHROME P450 3A4; MEFLOQUINE; ANTIMALARIAL AGENT; CYTOCHROME P450;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; INFECTION; MALARIA; MALE; MOUSE; NONHUMAN; PARASITEMIA; PLASMODIUM YOELII; PLASMODIUM YOELII INFECTION; PLASMODIUM YOELII NIGERIENSIS; PRIORITY JOURNAL; TREATMENT RESPONSE; ANIMAL; DOSE CALCULATION; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; METABOLISM; METHODOLOGY; MORTALITY; MULTIDRUG RESISTANCE; ORAL DRUG ADMINISTRATION; PARASITOLOGY; PATHOLOGY; RODENT DISEASE; SURVIVAL RATE; THAILAND;

ARTESUNATE; MUS; PLASMODIUM FALCIPARUM; PLASMODIUM YOELII NIGERIENSIS;

ADMINISTRATION, ORAL; ANIMALS; ANTIMALARIALS; CLARITHROMYCIN; CYTOCHROME P-450 ENZYME SYSTEM; DRUG DOSAGE CALCULATIONS; DRUG RESISTANCE, MULTIPLE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; MALARIA; MALE; MEFLOQUINE; MICE; PARASITEMIA; PLASMODIUM YOELII; RODENT DISEASES; SURVIVAL RATE; THAILAND;

EID: 80053056907     PISSN: 00311820     EISSN: 14698161     Source Type: Journal    
DOI: 10.1017/S0031182011000850     Document Type: Article

References (33)

1. Awasthi, A., Dutta, G. P., Bhakuni, V. and Tripathi, R. (2004). Resistance reversal action of ketoconazole against mefloquine resistance of Plasmodium yoelii nigeriensis (MDR). Experimental Parasitology 107, 115-119. (Pubitemid 39194162)
2. Baldwin, J., Gabriel, E. F., Friedman, P.A., Remy, D.C. (1991). Method of treating malaria with cyproheptadine derivatives. United States Patent 5021426.
3. Brophy, D. F., Isreal, D. S., Pastor, A., Gillotin, C., Chittick, G. E., Symonds, W.T., Lou, Y., Sadler, B.M. and Polk, R. E. (2000). Pharmacokinetic interaction between Amprenavir and clarithromycin in healthy male volunteers. Journal of Antimicrobial Agents and Chemotherapy 44, 978-984. (Pubitemid 30165279)
4. Ciach, M., Zong, K., Kain, K.C. and Crandall, I. (2003). Reversal of mefloquine and quinine resistance in Plasmodium falciparum with NP30. Antimicrobial Agents and Chemotherapy 47, 2393-2396. (Pubitemid 36919435)
5. Dhawan, S., Awasthi, A., Tripathi, R., Puri, S. K. and Dutta, G. P. (2000). Reversal of chloroquine/mefloquine resistance of Plasmodium yoelii nigeriensis (MDR) by IFN-gamma and chloroquine resistance by Poly ICLC. Journal of Parasitic Diseases 24, 195-201.
6. Fontaine, F., Sousa, G.de., Burcham, P. C., Duchene, P. and Rahmani, R. (2000). Role of cytochrome P450 3A in the metabolism of mefloquine in human and animal hepatocytes. Life Sciences 66, 2193-2212. (Pubitemid 30313087)
7. Frederich, M., Hayette, M. P., Tits, M., Mol, P. D. and Angenot, L. (2001). Reversal of chloroquine and mefloquine resistance in Plasmodium falciparum by the two monoindole alkaloids, Icajine and Isoretuline. Planta Medicine 67, 523-27. (Pubitemid 32800417)
8. Gupta, S., Thapar, M. M., Wernsdorfer, W. H. and Bjorkman, A. (2002). In vitro interactions of artemisinin with atovaquone, quinine and mefloquine against plasmodium falciparum. Antimicrobial Agents and Chemotherapy 46, 1510-1515. (Pubitemid 34415335)
9. th Annual Meeting of The American Society of Tropical Medicine and Hygiene, Washington, D.C. 4-8 December, 1988. p. 218.
10. Looareesuwan, S., Wilariatana, P., Viravan, C., Vanijanonta, S., Pitisutithum, P. and Kyle, D. E. (1997). Open randomized trial of oral artemether alone and a sequential combination with mefloquine for acute uncomplicated falciparum malaria. American Journal Tropical Medicine & Hygiene 56, 613-617. (Pubitemid 27318581)
11. Malhotra-Kumar, S., Lammens, C., Coenen, S., Herck, K. V. and Goossens, H. (2007). Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: A randomised, double-blind, placebo-controlled study. Lancet 369, 482-490. doi:10.1016/S0140-6736(07)60235-9. PMID 17292768. (Pubitemid 46209315)
12. Mathis, A., Wild, E. C., Boettger, E. C., Kapel, C. M. O. and Deplazes, C. P. (2005). The mitochondrial ribosome as target for macrolide antibiotic clarithromycin in the helminth Echinococcus multiocularis. Antimicrobial Agents and Chemotherapy 49, 3251-3255. (Pubitemid 41060568)
13. Mathis, A., Wild, P., Deplazes, P. and Boettger, E. C. (2004). The mitochondrial ribosome of the protozoan Acanthamoeba castellanii is the target for macrolide antibiotics. Molecular and Biochemical and Parasitology 135, 225-229.
14. Nosten, F., Kuile, F. T., Chongsaphajaisiddhi, T., White, N.J., Kuile, F. T., Luxemburger, C., Webster, H. K., Edstein, M., Phajpun, L., Thew, K. L. and White, N. J. (1991). MFQ resistant falciparum malaria on the Thailand-Burmese border. Lancet, 337, 1140-1143.
15. Odoula, A. M., Omitowoju, G. O., Genera, L., Kyle, D. E., Milhouse, W. K., Sowunmi, A. and Salako, L. A. (1993). Reversal of mefloquine resistance with penfluoridol in isolates of Plasmodium falcipar-um from southwest Nigeria. Transaction of Royal Society of Tropical Medicine and Hygiene 87, 81-83.
16. Pai, M. P., Graci, D. M. and Amesden, G. W. (2000). Macrolide-drug interaction: An update. Annals of Pharmacotherapy 34, 495-513.
17. Peters, W. and Robinson, B. L. (1991). The chemotherapy of rodent malaria. XLVI Reversal of mefloquine resistance in rodent Plasmodium. American Journal of Tropical Medicine and Parasitology 88, 5-10.
18. Pinto, A. G., Wanq, Y. H., Chalasani, N., Skaar, T., Kolwankar, D., Gorski, J. C., Lianqpunsaqul, S., Hamman, M. A., Arefayene, M. and Hall, S.D. (2005). Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression. Clinical Pharmacological Therapy 77, 178-188. (Pubitemid 40269133)
19. Price, R. N., Luxemburger, C., van Vugt, M., Simpson, J., Phaipun, L., Chongsuphajaisiddhi, T., Nosten, F. and White, N. J. (1998). Artesunate and mefloquine in the treatment of uncomplicated multidrug-resistant hyperparasitaemic falciparum malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene 92, 207-211. (Pubitemid 28200804)
20. Price, R. N., Nosten, F., Luxemburger, C., Kham, A. M., Brockman, A., Chongsuphajaisiddhi, T. and White, M. N. J. (1995). Artesunate versus artemether in combination with mefloquine for the treatment of multidrug resistant falciparum malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene 89, 523-527.
21. Ridtitid, W., Wongnawa, M.W., Mahatthanatrakul, W., Raungsri, N. and Sunbhanich, M. (2005). Ketoconazole increases plasma concentrations of antimalarial mefloquine in healthy human volunteers. Journal of Clinical Pharmacy and Therapeutics 30, 285-290. (Pubitemid 41603053)
22. Sinclair, D., Olliaro, P. and Garner, P. (2010). Guest Editorial: Artemisinin-based combination therapy for malaria, but which one? Clinical Evidence 8, 1-4.
23. Suzuki, A., Ilda, I., Hirota, M., Akimoto, M., Higuchi, S., Suwa, T., Tani, M., Ishizaki, T. and Chiba, K. (2003). Cyp isoforms invoved in the metabolism of CLTR in vitro: Comparison between the identification from disappearance rate and that from formation rate of metabolites. Drug Metabolism and Pharmacokinetics 18, 104-113.
24. 450 inhibitor, against mefloquine resistant malaria. Parasitology 130, 475-479. (Pubitemid 40685761)
25. Westphal, J. F. (2000). Macrolide induced clinically relevant drug interactions with cytochrome P450 A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin. British Journal of Clinical Pharmacology 50, 285-295.
26. Wisedpanichkij, R., Chaijaroenkul, W., Sangsuwan, P., Tantisawat, J., Boonprasert, K. and Bangchang, K. N. (2009). In vitro antimalarial interactions between mefloquine and cytochrome P450 inhibitors. Acta Tropica 112, 12-15.
27. World Health Organization (2001). Antimalarial drug combination therapy: Report of WHO Technical Combination, Geneva, Switzerland. (WHO/CDS/RBM/ 2001·35)
28. World Health Organization (2004) The World Health Report 2004-Changing Story. World Health Organization, Geneva, Switzerland.
29. World Health Organization (2006). Facts on ACTs (Artemisinin Based Combinations): An Update. World Health Organization, Geneva, Switzerland.
30. World Health Organization (2008). Malaria Report. World Health Organization, Geneva.
31. World Health Organization (2010a). Malaria-Disease Burden in SEA Region. World Health Organization, Geneva, Switzerland.
32. nd Edn. World Health Organization, Geneva, Switzerland.
33. Zhou, S. F. (2008). Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Current Drug Metabolism 9, 310-322.